Clinical Observation of Caspofungin Acetate in the Treatment of Invasive Pulmoary Fungal Infection
10.6039/j.issn.1001-0408.2016.17.40
- VernacularTitle:醋酸卡泊芬净治疗侵袭性肺部真菌感染的临床观察
- Author:
Suxia LIU
;
Jing CAI
;
Yaping XU
;
Liping GUO
- Publication Type:Journal Article
- Keywords:
Invasive pulmonary fungal infection;
Caspofungin acetate;
Itraconazole;
Efficacy;
ADR
- From:
China Pharmacy
2016;27(17):2420-2421,2422
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the clinical efficacy and safety of caspofungin acetate in the treatment of invasive pulmo-nary fungal infection(IPFI). METHODS:70 patients with IPFI were selected and randomly divided into observation group(40 cas-es) and control group (30 cases). Control group was given Itraconazole injection with initial dose of 250 mg,bid,decreasing to 200 mg,qd,2 days later;observation group was given Caspofungin acetate injection 70 mg on the first day,decreasing to 50 mg, ivgtt,qd,within 1 h. Clinical efficacy,the rate of nacterial smear negative conversion and ADR were observed in 2 groups. RE-SULTS:The total effective rate of observation group was 92.50%,which was significantly higher than that of control group (76.67%);the rate of nacterial smear negative conversion was 72.00% in observation group,which was significantly higher than that of control group(42.10%);the incidence of ADR was 7.50%in observation group,which was significantly lower than that of control group (13.33%),with statistical significance (P<0.05). CONCLUSIONS:Caspofungin acetate is effective for IPFI with low incidence of ADR.
